---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-110462"
form_type: "8-K"
ticker: "TRVI"
cik: "0001563880"
company_name: "Trevi Therapeutics, Inc."
filed_at: "2024-10-01T23:59:59+00:00"
generated_at: "2026-05-30T23:21:11.924821+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Trevi Therapeutics names James Cassella Chief Development Officer; CMO David Clark departs

## Summary
- James Cassella appointed CDO effective Sept 30, 2024; he resigned from the Board on that date.
- David Clark stepped down as CMO effective Sept 27, 2024, to care for a family member; will consult at $400/hour.
- Cassella has 35+ years CNS drug development experience, including CDO at Concert Pharmaceuticals and FDA approval of Leqselvi.
- Company is advancing Haduvio for IPF cough and refractory chronic cough; pivotal program and regulatory submission planned.

## SEC filing metadata
- accession: 0000950170-24-110462
- form_type: 8-K
- ticker: TRVI
- cik: 0001563880
- company_name: Trevi Therapeutics, Inc.
- filed_at: 2024-10-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563880/000095017024110462/0000950170-24-110462-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563880/000095017024110462/trvi-20240927.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-110462
- JSON: https://secwatch.observer/filing/0000950170-24-110462.json
- Plain text: https://secwatch.observer/filing/0000950170-24-110462.txt

## Key facts
- Executive change
  David Clark departed as Chief Medical Officer at Trevi Therapeutics, Inc..
  - Action: stepped down
  - Role: Chief Medical Officer
  source text: David Clark, MBChB, MRCP, had stepped down as the Company’s Chief Medical Officer, effective as of September 27, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1563880/000095017024110462/0000950170-24-110462-index.htm
- Executive change
  James Cassella resigned as Member of the Board of Directors at Trevi Therapeutics, Inc..
  - Action: resigned
  - Role: Member of the Board of Directors
  source text: Dr. Cassella resigned from his position as a member of the Board of Directors of the Company, effective as of September 30, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1563880/000095017024110462/0000950170-24-110462-index.htm
- Executive change
  James Cassella was appointed as Chief Development Officer at Trevi Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Development Officer
  source text: announced that James Cassella, Ph.D., had agreed to join the Company as its Chief Development Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1563880/000095017024110462/0000950170-24-110462-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.